Fibroblast Growth Factor 23 Associates with Death in Critically Ill Patients
Copyright © 2018 by the American Society of Nephrology..
BACKGROUND AND OBJECTIVES: Dysregulated mineral metabolism is a common and potentially maladaptive feature of critical illness, especially in patients with AKI, but its association with death has not been comprehensively investigated. We sought to determine whether elevated plasma levels of the osteocyte-derived, vitamin D-regulating hormone, fibroblast growth factor 23 (FGF23), are prospectively associated with death in critically ill patients with AKI requiring RRT, and in a general cohort of critically ill patients with and without AKI.
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We measured plasma FGF23 and other mineral metabolite levels in two cohorts of critically ill patients (n=1527). We included 817 patients with AKI requiring RRT who enrolled in the ARF Trial Network (ATN) study, and 710 patients with and without AKI who enrolled in the Validating Acute Lung Injury biomarkers for Diagnosis (VALID) study. We hypothesized that higher FGF23 levels at enrollment are independently associated with higher 60-day mortality.
RESULTS: In the ATN study, patients in the highest compared with lowest quartiles of C-terminal (cFGF23) and intact FGF23 (iFGF23) had 3.84 (95% confidence interval, 2.31 to 6.41) and 2.08 (95% confidence interval, 1.03 to 4.21) fold higher odds of death, respectively, after adjustment for demographics, comorbidities, and severity of illness. In contrast, plasma/serum levels of parathyroid hormone, vitamin D metabolites, calcium, and phosphate were not associated with 60-day mortality. In the VALID study, patients in the highest compared with lowest quartiles of cFGF23 and iFGF23 had 3.52 (95% confidence interval, 1.96 to 6.33) and 1.93 (95% confidence interval, 1.12 to 3.33) fold higher adjusted odds of death.
CONCLUSIONS: Higher FGF23 levels are independently associated with greater mortality in critically ill patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Clinical journal of the American Society of Nephrology : CJASN - 13(2018), 4 vom: 06. Apr., Seite 531-541 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Leaf, David E [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 11.10.2019 Date Revised 14.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2215/CJN.10810917 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM281766045 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM281766045 | ||
| 003 | DE-627 | ||
| 005 | 20240314233403.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2215/CJN.10810917 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1328.xml |
| 035 | |a (DE-627)NLM281766045 | ||
| 035 | |a (NLM)29519954 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Leaf, David E |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Fibroblast Growth Factor 23 Associates with Death in Critically Ill Patients |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.10.2019 | ||
| 500 | |a Date Revised 14.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2018 by the American Society of Nephrology. | ||
| 520 | |a BACKGROUND AND OBJECTIVES: Dysregulated mineral metabolism is a common and potentially maladaptive feature of critical illness, especially in patients with AKI, but its association with death has not been comprehensively investigated. We sought to determine whether elevated plasma levels of the osteocyte-derived, vitamin D-regulating hormone, fibroblast growth factor 23 (FGF23), are prospectively associated with death in critically ill patients with AKI requiring RRT, and in a general cohort of critically ill patients with and without AKI | ||
| 520 | |a DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We measured plasma FGF23 and other mineral metabolite levels in two cohorts of critically ill patients (n=1527). We included 817 patients with AKI requiring RRT who enrolled in the ARF Trial Network (ATN) study, and 710 patients with and without AKI who enrolled in the Validating Acute Lung Injury biomarkers for Diagnosis (VALID) study. We hypothesized that higher FGF23 levels at enrollment are independently associated with higher 60-day mortality | ||
| 520 | |a RESULTS: In the ATN study, patients in the highest compared with lowest quartiles of C-terminal (cFGF23) and intact FGF23 (iFGF23) had 3.84 (95% confidence interval, 2.31 to 6.41) and 2.08 (95% confidence interval, 1.03 to 4.21) fold higher odds of death, respectively, after adjustment for demographics, comorbidities, and severity of illness. In contrast, plasma/serum levels of parathyroid hormone, vitamin D metabolites, calcium, and phosphate were not associated with 60-day mortality. In the VALID study, patients in the highest compared with lowest quartiles of cFGF23 and iFGF23 had 3.52 (95% confidence interval, 1.96 to 6.33) and 1.93 (95% confidence interval, 1.12 to 3.33) fold higher adjusted odds of death | ||
| 520 | |a CONCLUSIONS: Higher FGF23 levels are independently associated with greater mortality in critically ill patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Research Support, U.S. Gov't, Non-P.H.S. | |
| 650 | 4 | |a Acute Kidney Injury | |
| 650 | 4 | |a Acute Lung Injury | |
| 650 | 4 | |a Biomarkers | |
| 650 | 4 | |a Calcium, Dietary | |
| 650 | 4 | |a Cohort Studies | |
| 650 | 4 | |a Comorbidity | |
| 650 | 4 | |a Confidence Intervals | |
| 650 | 4 | |a Critical Illness | |
| 650 | 4 | |a Demography | |
| 650 | 4 | |a Fibroblast Growth Factors | |
| 650 | 4 | |a Humans | |
| 650 | 4 | |a Minerals | |
| 650 | 4 | |a Osteocytes | |
| 650 | 4 | |a Phosphates | |
| 650 | 4 | |a Renal Replacement Therapy | |
| 650 | 4 | |a Vitamin D | |
| 650 | 4 | |a acute renal failure | |
| 650 | 4 | |a fibroblast growth factor 23 | |
| 650 | 4 | |a parathyroid hormone | |
| 650 | 4 | |a renal dialysis | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a FGF23 protein, human |2 NLM | |
| 650 | 7 | |a Fibroblast Growth Factors |2 NLM | |
| 650 | 7 | |a 62031-54-3 |2 NLM | |
| 650 | 7 | |a Fibroblast Growth Factor-23 |2 NLM | |
| 650 | 7 | |a 7Q7P4S7RRE |2 NLM | |
| 700 | 1 | |a Siew, Edward D |e verfasserin |4 aut | |
| 700 | 1 | |a Eisenga, Michele F |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Karandeep |e verfasserin |4 aut | |
| 700 | 1 | |a Mc Causland, Finnian R |e verfasserin |4 aut | |
| 700 | 1 | |a Srivastava, Anand |e verfasserin |4 aut | |
| 700 | 1 | |a Alp Ikizler, T |e verfasserin |4 aut | |
| 700 | 1 | |a Ware, Lorraine B |e verfasserin |4 aut | |
| 700 | 1 | |a Ginde, Adit A |e verfasserin |4 aut | |
| 700 | 1 | |a Kellum, John A |e verfasserin |4 aut | |
| 700 | 1 | |a Palevsky, Paul M |e verfasserin |4 aut | |
| 700 | 1 | |a Wolf, Myles |e verfasserin |4 aut | |
| 700 | 1 | |a Waikar, Sushrut S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical journal of the American Society of Nephrology : CJASN |d 2006 |g 13(2018), 4 vom: 06. Apr., Seite 531-541 |w (DE-627)NLM172123720 |x 1555-905X |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2018 |g number:4 |g day:06 |g month:04 |g pages:531-541 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2215/CJN.10810917 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2018 |e 4 |b 06 |c 04 |h 531-541 | ||